Objective. Long noncoding RNAs (lncRNAs) have been strongly associated with various types of cancer. The present study aimed at exploring the diagnostic and prognostic value of lncRNA Zinc finger protein 667-antisense RNA 1 (ZNF667-AS1) in glioma patients. Patients and Methods. The expressions of ZNF667-AS1 were detected in 155 glioma tissues and matched normal brain tissue samples by qRT-PCR. The receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of ZNF667-AS1. The association between the ZNF667-AS1 expression and clinicopathological characteristics was analyzed by the chi-square test. The Kaplan-Meier method was performed to determine the influence of the ZNF667-AS1 expression on the overall survival and disease-free survival of glioma patients. The Cox regression analysis was used to evaluate the effect of independent prognostic factors on survival outcome. Cell proliferation was measured by the respective cell counting Kit-8 (CCK-8) assays. Results. We observed that ZNF667-AS1 was significantly upregulated in glioma tissues compared to normal tissue samples (). Higher levels of ZNF667-AS1 were positively associated with the WHO grade () and KPS score (). ROC assays revealed that the high ZNF667-AS1 expression had an AUC value of 0.8541 (95% CI: 0.8148 to 0.8934) for glioma. Survival data revealed that glioma patients in the high ZNF667-AS1 expression group had significantly shorter 5-year overall survival () and disease-free survival () time than those in the low ZNF667-AS1 expression group. Moreover, multivariate analyses confirmed that the ZNF667-AS1 expression was an independent predictor of the overall survival and disease-free survival for glioma patients. Functionally, we found that knockdown of ZNF667-AS1 suppressed the proliferation of glioma cells. Conclusions. Our results suggest that ZNF667-AS1 could be used as a potential diagnostic and prognostic biomarker in glioma.

中文翻译：

---

分析长链非编码 RNA ZNF667-AS1 作为胶质瘤患者诊断和预后的潜在生物标志物

客观。长链非编码 RNA (lncRNA) 与各种类型的癌症密切相关。本研究旨在探讨 lncRNA 锌指蛋白 667-反义 RNA 1 (ZNF667-AS1) 在胶质瘤患者中的诊断和预后价值。患者和方法. 通过qRT-PCR在155个胶质瘤组织和匹配的正常脑组织样本中检测到ZNF667-AS1的表达。采用受试者工作特征 (ROC) 曲线估计 ZNF667-AS1 的诊断价值。采用卡方检验分析ZNF667-AS1表达与临床病理特征的相关性。采用 Kaplan-Meier 方法确定 ZNF667-AS1 表达对胶质瘤患者总生存期和无病生存期的影响。Cox回归分析用于评估独立预后因素对生存结果的影响。通过相应的细胞计数 Kit-8 (CCK-8) 测定法测量细胞增殖。结果. 我们观察到与正常组织样本相比，神经胶质瘤组织中的 ZNF667-AS1 显着上调。）。较高水平的 ZNF667-AS1 与 WHO 等级呈正相关（)和 KPS 分数 (）。ROC 分析显示，高 ZNF667-AS1 表达对胶质瘤的 AUC 值为 0.8541（95% CI：0.8148 至 0.8934）。生存数据显示，高 ZNF667-AS1 表达组的胶质瘤患者的 5 年总生存期显着缩短。)和无病生存 ()时间比低 ZNF667-AS1 表达组的时间长。此外，多变量分析证实，ZNF667-AS1 表达是胶质瘤患者总生存期和无病生存期的独立预测因子。在功能上，我们发现 ZNF667-AS1 的敲低抑制了神经胶质瘤细胞的增殖。结论。我们的结果表明 ZNF667-AS1 可用作胶质瘤的潜在诊断和预后生物标志物。